 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
It is a big bandwagon...KOOL trades Nasdaq around 2 1/2: (COMTEX) B: Stem Cell Viability Study Presented by THERMOGENESIS CORP B: Stem Cell Viability Study Presented by THERMOGENESIS CORP. At FDA/NHLBI Stem Cell Conference; Studies Contribute to Growing Body of Scientific Knowledge On Stem Cells RANCHO CORDOVA, Calif., Aug 24, 2000 (BW HealthWire) -- THERMOGENESIS CORP. (Nasdaq:KOOL) announced that preliminary results, presented by Phil Coelho, Chairman & CEO of THERMOGENESIS CORP., suggest that cell viability of stem cells may be adversely affected by stresses that develop during exposure to Transient Warming Events (TWE). The results were announced at the Unrelated Allogeneic Cord Blood Banking and Transplant Forum held by FDA/NHLBI in Bethesda, MD on August 14 & 15, 2000 and The Fourth International Symposium on Hematopoietic Stem Cell Transplantation Conference in Tokyo, Japan on July 6, 2000. TWEs may occur as many as 20 to 30 times prior to transplant when stem cell units are prepared utilizing conventional cryogenic processing equipment. With conventional processing equipment, the stem cell units are exposed to the ambient air as they are transferred from the controlled-rate freezer to a quarantine freezer, from the quarantine to the storage freezer, during storage as different units stored in the same rack are removed, when removed from storage and transferred to a cryo shipper, and at least once more when the unit is placed in the storage dewar at the transplant center. Tests carried out at the New York Blood Center's Placental Blood Program indicated that losses of up to 20% of viable colony forming cells (CFU-C) may occur with only five TWEs in which the temperature of the frozen graft rises to -80 degrees C and losses of up to 50% if the frozen graft rises to -40 degrees C. James Godsey, Ph.D., President & COO of THERMOGENESIS CORP. noted that ".... The BioArchive System, which was designed by THERMOGENESIS CORP. to reduce the incidence and severity of TWEs by more than 90%, is demonstrably the international standard for collecting, processing, and archiving cryopreserved hematopoietic stem cells sourced from placental/cord blood (PCB)." PCB stem cells are used to reconstitute the hematopoietic and immune systems of patients who have undergone high-dose chemotherapy and radiation to combat diseases such as leukemias, lymphomas, diverse inherited anemias such as sickle cell anemia and thalassemia and other genetic diseases. BioArchive systems are now in use by the major cord blood banks in U.S.A., Germany, Finland, Spain, England, Belgium, Japan, China, Taiwan and Vietnam. About the BioArchive System The BioArchive System uses THERMOGENESIS CORP.'s proprietary computer-driven liquid nitrogen robotic system to cryopreserve and archive up to 3,626 25ml units of PCB stem cells that have been collected and preserved in proprietary sterile plastic bag sets. The BioArchive System tracks identification and location for each unit and performs robotic retrieval of each unique tissue-typed unit for use. The BioArchive System operates to freeze, place and retrieve samples without exposing other archived samples to detrimental temperature changes. The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to IND sites which have received FDA approvals for use with stem cell storage for transplant into unrelated patients. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. THERMOGENESIS CORP. BioArchive system is currently intended for preservation of blood components and blood products and would require FDA 510(k) clearance for some additional claims. Use of the BioArchive System in the above applications may be subject to certain regulations. About THERMOGENESIS CORP. THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years. The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. CONTACT: THERMOGENESIS CORP. James H. Godsey, 916/858-5100 jgodsey@thermogenesis.com www.thermogenesis.com URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2000 Business Wire. All rights reserved. -0- KEYWORD: CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES *** end of story *** | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |